The Endocannabinoid System Promotes Astroglial Differentiation by Acting on Neural Progenitor Cells

Tania Aguado,1 Javier Palazuelos,1 Kriszta Monory,2 Nephi Stella,3 Benjamin Cravatt,4 Beat Lutz,2 Giovanni Marsiscono,2 Zaal Kokaia,2 Manuel Guzmán,4 and Ismael Galve-Roperh2

1Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, 28040 Madrid, Spain, 2Max-Planck Institute of Psychiatry, 80804 Munich, Germany, 3Department of Pharmacology, Washington University, Seattle, Washington 98195, 4The Skaggs Institute for Chemical Biology and Department of Cell Biology, The Scripps Research Institute, La Jolla, California 92037, and 5Laboratory of Neural Stem Cell Biology, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, University Hospital, SE-221 84 Lund, Sweden

Endocannabinoids exert an important neuromodulatory role via presynaptic cannabinoid CB1 receptors and may also participate in the control of neural cell death and survival. The function of the endocannabinoid system has been extensively studied in differentiated neurons, but its potential role in neural progenitor cells remains to be elucidated. Here we show that the CB1 receptor and the endocannabinoid-inactivating enzyme fatty acid amide hydrolase are expressed, both in vitro and in vivo, in postnatal radial glia (RC2+/cells) and in adult nestin type I (nestin+/GFAP+) neural progenitor cells. Cell culture experiments show that CB1 receptor activation increases progenitor proliferation and differentiation into astroglial cells in vitro. In vivo analysis evidences that, in postnatal CB1−/− mouse brain, progenitor proliferation and astrogliogenesis are impaired. Likewise, in adult CB1−/− deficient mice, neural progenitor proliferation is decreased but is increased in fatty acid amide hydrolase-deficient mice. In addition, endocannabinoid signaling controls neural progenitor differentiation in the adult brain by promoting astroglial differentiation of newly born cells. These results show a novel physiological role of endocannabinoids, which constitute a new family of signaling cues involved in the regulation of neural progenitor cell function.

Key words: cannabinoid; neural progenitor; proliferation; astrogliogenesis; radial glia; CB1 receptor

Introduction

The recent identification of neural progenitor (NP) cells resident in the subventricular zone, the dentate gyrus of the hippocampus, and the olfactory bulb has provided a biological explanation for the neurogenic process that occurs in these restricted adult brain areas (Alvarez-Buylla and Lim, 2004; Lie et al., 2004). Cells expressing certain markers of astroglial cells, such as glial fibrillary acidic protein (GFAP), act as multipotent self-renewing progenitors that can differentiate into the major brain cellular lineages (Doetsch et al., 1999; Laywell et al., 2000; Seri et al., 2001). For instance, selective cell ablation by GFAP-driven thymidine kinase expression and ganciclovir administration elegantly demonstrated the nature of postnatal and adult brain NPs (Imura et al., 2003; Garcia et al., 2004). The existence of this adult GFAP-positive NP cell subpopulation is in agreement with the ability of radial glia to act as parental cells (Malatesta et al., 2000; Noctor et al., 2001) besides their well known migratory scaffold role during cortex development (Rakic, 2003). During development, radial progenitors evolve to GFAP-expressing cells with a concomitant decrease in RC2 expression (Tramontin et al., 2003; Merkle et al., 2004). In particular, double nestin+/GFAP+ cells (type I cells) are proposed to constitute the adult neural stem cell population as a continuum of the embryonic neural stem cell compartment (Alvarez-Buylla and Lim, 2004; Kempermann et al., 2004).

Although many extracellular signals are known to be involved in the regulation of NP cell proliferation and differentiation (Temple, 2001; Ross et al., 2003), the precise mechanisms involved in cell fate determination remain to be fully elucidated. Growth factors, such as epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF), act as key regulators of NP cell proliferation and differentiation (Temple, 2001). In addition, a variety of signals participate in the regulation of NP differentiation to either neurogenesis or gliogenesis (Ross et al., 2003; Ever and Gaiano, 2005). The endocannabinoids (eCBs) anandamide [N-arachidonoylthanolamine (AEA)] and 2-arachidonoylglycerol (2AG), the endogenous counterparts of plant-derived cannabinoids, exert a neuromodulatory role by controlling neurotransmitter release via presynaptic CB1 receptors (Piomelli, 2003). Cannabinoids may also take part in the control of neural...
cell fate, thereby modulating the balance between cell death and survival (Mechoulam et al., 2002; Guzmán, 2003). eCBs are generated on demand as a consequence of brain injury (Mechoulam et al., 2002), and CB1 receptor engagement is responsible for their neuroprotective action (Marsicano et al., 2003). Moreover, cannabinoid administration protects neurons from different brain insults, such as ischemia, glutamatergic excitotoxicity, oxidative stress, and trauma (Mechoulam et al., 2002). CB1 expression is developmentally regulated, with a peak of expression in the rat hippocampus that coincides with the initiation of gliogenesis in vivo (Fernández-Ruiz et al., 2001). The function of the eCB system has been extensively studied in differentiated neurons, and its potential implication in the regulation of NP cell fate has been suggested (Rueda et al., 2002; Jin et al., 2004; Aguado et al., 2005). However, its precise role in the regulation of cell lineage commitment and NP differentiation remains to be elucidated. Together, these evidences prompted us to study whether NP cells express a functional eCB system and, if so, whether it regulates NP differentiation.

Materials and Methods

Materials. The following materials were kindly donated: nestin-green fluorescent protein (GFP) transgenic mice (G. Enikolopov, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY), GL1-pGL3 (T. Taga, Kumamoto University, Kumamoto, Japan), SR141716 [N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole carboxamide] (Sanofi-Aventis, Montpellier, France), anti-mouse CB1 polyclonal antibody (K. Mackie, Washington University, Seattle, WA), anti-mouse polysialylated neural cell adhesion molecule (PSA-NCAM) monoclonal antibody (I. Azcoitia, Complutense University, Madrid, Spain), anti-mouse phosphorylated-S55 vimentin monoclonal 4A4 antibody (V. Cerdeño, University of California San Francisco, San Francisco, CA), neuroepithelial expression reporter vector (pNERV) nestin-β-galactosidase (β-gal) reporter (Panchision et al., 2001), and monoclonal anti-O4 antibody (A. Rodríguez-Peña, Consejo Superior de Investigaciones Científicas, Madrid, Spain) (Sommer and Schachner, 1981). Cyclohexyl carbamic acid 3-carbamoyl-biphenyl-3-yl ester (URB597) and 2AG were from Cayman Chemicals (Ann Arbor, MI), mouse monoclonal anti-nestin, anti-vimentin, and rabbit polyclonal anti-fatty acid amide hydrolase (FAAH) antibodies were from Chemicon (Temecula, CA), monoclonal anti-Ki67 (SP6) antibody from LabVision (Fremont, CA), and rabbit polyclonal anti-glutamate-aspartate transporter (GLAST) was from Alpha Diagnostic (San Leandro, CA). Recombinant human EGF and bFGF were from R & D Systems (Minneapolis, MN). WIN-55,212-2 [R(+)-(2,3-dihydro-5-methyl-3-[(4-morpholiny)methyl]pyrro][1,2,3-de]-1,4- benzoaxazin-6-yl)](1-naphthalenyl) methanone monomethanesulfonate], AEA, mouse monoclonal anti-β-tubulin III, anti-GFAP, and anti-α-tubulin antibodies were from Sigma (St. Louis, MO). Monoclonal anti-RC2 antibody was from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA).

Neural progenitor cell culture. NPs were obtained from the dissected cortices of 2-d-old rat pups and grown in chemically defined medium formed by Dulbecco’s modified Eagle’s and F-12 media supplemented

Figure 1. The endocannabinoid system is expressed in postnatal neural progenitors. A, Immunofluorescence was performed to assess CB1 and FAAH (red) expression in nestin-GFP-derived neurospheres. Scale bar, 20 μm. B, Immunofluorescence was performed with CB1 or FAAH antibodies (red) in combination with nestin, RC2, vimentin, or phosphorylated vimentin (4A4) antibodies (green). In addition, triple labeling was performed with CB1 (blue), nestin (green), and BrdU (red) antibodies. Scale bars, 20 μm. C, The presence of CB1 receptor and FAAH mRNA was determined by RT-PCR in NPs, differentiated neurons (N), and differentiated astroglial cells (A).
with N2 (Invitrogen, Carlsbad, CA), 0.6% glucose, nonessential amino acids, 50 mM HEPES, 2 μg/ml heparin, 20 ng/ml EGF, and 20 ng/ml bFGF. Clonal neurospheres were derived from nonadherent cultures of NPs (1000 cells/ml). Adherent NP cultures in chemically defined medium were grown in polyornithine-coated plates, and differentiation experiments were performed during the indicated times in the presence of the indicated stimuli after overnight growth factor deprivation. Differentiation experiments of at least three independent cultures were performed by quantification of the cells that express the indicated antigens and total cells stained with Hoechst 33258. A minimum of 10 fields were scored in a double-blinded manner to minimize subjective interpretations. Quantified fields were selected randomly by visualizing total cells with microscope Hoechst filter. Clonal analysis was performed by quantification of differentiation of single-cell-derived neurospheres and triple immunofluorescence with anti-

**Table 1: CB1 expression and Cell proliferation**

<table>
<thead>
<tr>
<th>Condition</th>
<th>CB1 expression (%)</th>
<th>Cell proliferation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nestin+GFAP*</td>
<td>49 ± 14</td>
<td>136 ± 11*</td>
</tr>
<tr>
<td>Nestin/GFAP</td>
<td>10 ± 4</td>
<td>95 ± 8</td>
</tr>
<tr>
<td>Nestin GFAP*</td>
<td>25 ± 8</td>
<td>94 ± 15</td>
</tr>
<tr>
<td>Nestin GFAP</td>
<td>11 ± 5</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

**Figure 2.** Characterization of postnatal progenitor proliferation and astroglial differentiation. A, Distribution of the phenotypic analysis with the indicated cell markers of proliferating (Ki67*) cells after 16 h of differentiation. Representative immunofluorescence pictures of NPs at different stages of differentiation using the indicated markers (n.d., not determined). Scale bar, 30 μm. B, CB1 receptor distribution in the different cellular phenotypes (as above). Representative nestin+GFAP (CB1) and nestin+GFAP (CB1) cells (open arrow) are shown. Scale bar, 30 μm. C, Quantification of CB1 distribution compared with the proliferative effect induced by WIN-55,212-2 for each cell type. Significantly different from controls, *p < 0.01. E–F, Cannabinoid impact on NP differentiation. Quantification of the percentage of nestin (Q), GFAP (B), β-tubulin III (I), and nestin (G) cells versus total cell number at the indicated differentiation times in the presence of vehicle, WIN-55,212-2, or URB597 alone or with SR141716. Results correspond to three independent experiments. Significant differences between cannabinoid-treated versus control cells are shown. *WIN-55,212-2, URB597, p < 0.05; †WIN-55,212-2, URB597, p < 0.01.
erase activity was performed following the instructions of the manufacturer using Promega (Madison, WI) luciferase assay and a Lumat LB9507 luminometer (Berthold Technologies, Bad Wildbad, Germany). Transcriptional activation of the GFAP promoter was confirmed in some experiments by inclusion of renilla-derived luciferase activity as internal transfection control and determination by the Dual-Luciferase Reporter Promega assay system. β-gal activity was determined according to standard procedures.

mRNA detection and quantification. RNA was obtained with the RNeasy Protect kit (Qiagen, Hilden, Germany) using the RNase-free DNase kit. cDNA was subsequently obtained using the Superscript First-Strand cDNA synthesis kit (Roche Products, Welwyn Garden City, UK), and amplification of cDNA was performed with the following primers: rat CB1 sense, TCT CTG GAA GGC TCA CAG; rat CB1 antisense, TGT CTG TGG ACA CAG ACA TG (522 bp product); rat FAAH sense, TGG GCC CTG TCT GGG ATT TG; and rat FAAH antisense, CAG AGC TGG GGA ATG AAC GAC (340 bp product). CB1 PCR reactions were performed using the following conditions: 93°C for 1 min, two rounds (30 s at 59°C, 1 min at 72°C, and 30 s at 93°C), two rounds (30 s at 57°C, 1 min at 72°C, and 30 s at 93°C), and 35 cycles (30 s at 55°C, 1 min at 72°C, and 30 s at 93°C). FAAH PCR conditions were as follows: 3 min at 96°C and 35 cycles (30 s at 95°C, 30 s at 65°C, and 1 min at 72°C). Finally, after a final extension step at 72°C for 5 min, PCR products were separated on 1.5% agarose gels. Real-time quantitative PCR was performed with Taqman probes obtained from Applied Biosystems (Foster City, CA). Amplifications were run in a 7700 Real-time PCR system and obtained values adjusted using 18S RNA levels as reference.

Western blot. Western blot analysis was performed as described previously (Galve-Roperh et al., 2000). Cleared cell extracts were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membranes. After incubation with anti-GFAP or anti-nestin antibody, blots were developed with horseradish peroxidase-coupled secondary antibodies and enhanced chemiluminescence detection kit. Loading controls were performed with an anti-β-tubulin antibody. Densitometric quantification of the luminograms was performed using a GS-700 Imaging Densitometer (Bio-Rad, Hercules, CA) and MultiAnalyst software (Bio-Rad).

Animals and drug treatment. CB1 (Marsicano et al., 2002) and FAAH (Cravatt et al., 2001) knock-out mice generation has been described previously. Postnatal day 2 mice pups were obtained from heterozygote crossings, and mothers were injected with 100 mg/kg 5-bromo-2-deoxyuridine (BrdU) on gestational day 18.5. After dissection, brains were fixed, and the corresponding tail DNA was used for genotyping. Determination of postnatal in vivo cell fate was performed with CB1−/− and CB1+/− pups (n = 4 each). Adult CB1−/− and FAAH knock-out mice (3 months old) and their respective wild-type littersmates were injected intraperitoneally with cannabinoids promote astroglial differentiation in vitro. A, Immunofluorescence with anti-β-tubulin III (green) and GFAP (red) antibodies after a 48 h differentiation period of NP cells in the presence of vehicle (C), 30 nM WIN-55,212-2 alone or with 2 μM SR141716, 30 nM URB597 alone or with SR141716, and SR141716 alone. Scale bar, 30 μm. (Figure legend continues.)
50 mg/kg BrdU daily for 5 d and then perfused 1 d 

\[ n = 3, \text{CB}_1 \text{~and~} \text{CB}_2 \text{~mice} \] 

\[ n = 4, \text{FAAH} \text{~and~} \text{FAAH~} \text{~mice} \] 

\[ n = 3, \text{FAAH} \text{~and~} \text{FAAH} \text{~mice} \] 

Animal procedures were performed according to the European Union guidelines (86/609/EU) for the use of laboratory animals.

**Immunofluorescence and confocal microscopy.** Perfusion and immunofluorescence was performed in 12 μm postnatal brain sections and 30 μm coronal adult brain free-floating sections of mice, as described previously (Rueda et al., 2002; Aguado et al., 2005). Postnatal and adult brain sections were incubated with rat monoclonal anti-Brdu (Abcam, Cambridge, MA), mouse monoclonal anti-neuronal-specific nuclear protein (NeuN) (Sigma), and rabbit polyclonal anti-S100β (Swant, Bellinzona, Switzerland) antibodies, followed by secondary staining for rat, mouse, and rabbit IgGs with highly cross-adsorbed AlexaFluor 594, AlexaFluor 488, and AlexaFluor 647 secondary antibodies (Invitrogen), respectively. Preparations were examined using Laser Sharp 2000 software (Bio-Rad) and a Confocal Radiance 2000 coupled to Axiovert S100 TV microscope (Zeiss, Oberkochen, Germany) with three passes with a Kalman filter and a 1024 × 1024 collection box. Neurogenesis and astrogllogenesis were determined in a minimum of five brain sections per animal. A 1-in-5 series of adult hippocampal mouse sections located between 1.3 and 2.1 mm posterior to bregma were used. The number of cells was normalized to the area of the dentate gyrus of each 30 μm section, followed by the determination of the total positive cell number per animal. For studies assessing CB1 receptor and FAAH expression in the hippocampal subgranular zone, TOTO-3 iodide (Invitrogen) was used to stain cell nuclei, except when nestin-GFP sections were used. BrdU-positive cells were counted in the subgranular zone and granule cell layer of the dentate gyrus, and confirmation that BrdU staining revealed proliferating neural progenitors but not DNA-repairing cells was assessed by standard criteria.

CB1 staining was detected with a rabbit polyclonal anti-rat/mouse CB1 antibody directed against the first 77 residues of the protein (Rodriguez Aguado et al., 2001). Specificity of CB1 immunoreactivity was corroborated by preabsorption experiments in which 0.5 μg of the polyclonal antibody was preincubated with 20 μg of the antigenic peptide for 1 h at 37°C. In addition, specificity was unequivocally determined using postnatal and adult CB1−/− mice sections, in which no immunoreactivity was observed (data not shown) and allowed us to adjust optimal confocal microscope settings. Quantification of the distribution of CB1 and FAAH was obtained by the use of four postnatal or adult wild-type mice and cell counting of a minimum of 500 cells of the different phenotypes per animal.

**Statistical analysis.** Results shown represent the means ± SD of the number of experiments indicated in every case. Statistical analysis was performed by ANOVA. A post hoc analysis was made by the Student–Newman–Keuls test. In vivo data were analyzed by an unpaired Student’s t test.

### Results

**Expression of the endocannabinoid system in postnatal neural progenitors**

Several evidences indicate that the eCB system may be expressed by embryonic NP cells (Rueda et al., 2002; Aguado et al., 2005). However, its presence in postnatal NPs has not been assessed yet. NPs derived from nestin-GFP mice were obtained, and CB1 and FAAH immunofluorescence was determined by immunofluorescence. As shown in the merged images, nestin positive progenitors express both elements of the eCB signaling system (Fig. 1 A). In addition, postnatal NPs were obtained, and fluorescence-activated cell sorting analysis revealed a majority of nestin+NP cells (75 ± 2% of total cells), followed by a glial-like cell component (GFAP+ cells, 18 ± 6%) and a minor immature neuronal cell fraction (β-tubulin III+, 6 ± 2%). CB1 and FAAH expression was subsequently analyzed by immunofluorescence (Fig. 1 B) and reverse transcription (RT)-PCR (Fig. 1 C). NPs were shown to express nestin together with the CB1 receptor and FAAH. Accordingly, RC2- and vimentin-positive cells, common markers of radial glial cells (Paxley and de Vellis, 1984; Rakic, 2003), expressed the CB1 receptor (Fig. 1 B). These findings are in agreement with the presence of the receptor in actively dividing progenitors, identified by BrdU incorporation and nestin coexpression, as well as in cells immunostained for phosphorylated vimentin (4A4 antibody) (Fig. 1 B).

### Endocannabinoids induce postnatal astroglial differentiation in vitro in a CB1-dependent manner

The potential influence of cannabinoids in NP cell differentiation was determined in adherent NP cultures differentiated in the absence or presence of these compounds. Because cannabinoids exert a positive action on NP proliferation [16 h incubation with 30 μM WIN-55,212-2 (a synthetic cannabinoid agonist) or 30 μM URB597 (a selective FAAH inhibitor): 158 ± 17 and 239 ± 42 BrdU− cells, respectively, vs 100% in vehicle incubations], we identified by immunofluorescence the characteristics of the progenitor cells present in our model (Fig. 2). Quantification of the specific neural markers expressed by Ki67+ cells identified the existence of double nestin+GFAP− (18 ± 5%) and nestin+GFAP− (51 ± 7%) nests, and nestin+GFAP+ (5 ± 2%) cells. These subpopulations may represent different stages of postnatal NP development (Laywell et al., 2000; Gregg and Weiss, 2003; Imura et al., 2003; Tramontin et al., 2003; Alvarez-Buylla and Lim, 2004), in agreement with the observation that the majority of cells at the initiation of differentiation express vimentin (87 ± 10%). To determine which cell subpopulation responds to cannabinoid stimulation, the expression of CB1, and their proliferative response was determined in each case (Fig. 2 B). Nestin+GFAP− cells were shown to constitute the major phenotype of CB1−/− cells, and they responded preferentially to cannabinoid-induced proliferation, whereas the nestin+GFAP− and nestin+GFAP+ subpopulations were refractory to cannabinoid-induced proliferation.

The dynamics, under basal conditions, of the different cell populations during the differentiation process of NPs was then analyzed (Fig. 2 C–F). Nestin− cell number decreased along time with a parallel increase in GFAP+ cells. In addition, β-tubulin III+ cells increased along with differentiation. Oligodendrocytes were also observed (day 8, 9 ± 3% of total cell number). In addition, analysis of the evolution of the nestin+ population regarding GFAP expression revealed an early increase in nestin+GFAP− cells that ensued a time-dependent decline. In parallel to their reduction, the more differentiated population of nestin+GFAP+ cells increased along time (data not shown).

Cannabinoid incubation during the differentiation process induced a significant progliogenic action and an inhibitory effect on neuronal differentiation. As evidenced by immunofluorescence analysis, WIN-55,212-2, and URB597, and the CB1 ligands AEA and 2AG increased the number of GFAP+ cells with a concomitant decrease in β-tubulin III+ cells after 2 d of...
differentiation (Fig. 3A). Likewise, cannabinoids increased the number of cells labeled with the astroglial markers S100β and GLAST-1 (Fig. 3B, C). Cannabinoid action on NP differentiation was blocked by the selective CB1 antagonist SR141716 (Figs. 2, 3), therefore supporting the involvement of the CB1 receptor. The effect of cannabinoid exposure during the complete 8 d differentiation period (Fig. 2) was analyzed and provided similar results to the values obtained at differentiation day 2 (Fig. 3). In addition, cannabinoid influence on NP multipotency was evaluated by using single-cell-derived neurospheres. After differentiation, a large fraction of the progenitors analyzed (68%) generated the three major lineages of the CNS (neurons, astrocytes, and oligodendrocytes), and treatment with WIN-55,212-2 doubled the number of NPs generating only astroglial cells (Fig. 3D).

Cannabinoid regulation of GFAP and nestin expression

The impact of cannabinoids on astroglial differentiation prompted us to study the regulation of GFAP and nestin expression. Thus, WIN-55,212-2 and URB597 increased GFAP promoter-driven luciferase activity via CB1 receptor activation (Fig. 4A). Similarly, although to a lower extent, cannabinoid stimulation increased GFAP mRNA and protein levels. In addition, WIN-55,512-2 and URB597 initially (24 h) increased nestin reporter activity, mRNA, and protein levels (Fig. 4B), which accompanied their proliferative action (see above). At extended differentiation times (day 4), nestin expression was reduced (Fig. 4B), in line with the reduction of the NP pool (Fig. 2C) and the increased astroglial differentiation. Overall, these results show that eCBs promote postnatal NP differentiation into astroglial cells in vitro.

Lack of effect of cannabinoids on neural progenitor apoptosis

To assess whether the observed proglionic action of cannabinoids on NPs may be affected by their potential influence in progenitor cell death, we determined apoptosis during cannabinoid challenge. WIN-55,212-2 and URB597 did not reduce cell viability after 2 d of stimulation, as determined by terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL) staining (Fig. 5A) and trypan blue exclusion (data not shown). At longer incubation times, apoptotic cells were not evident anymore in the cultures in either the presence or absence of the cannabinoids. We subsequently analyzed whether CB1 receptor deficiency may alter hippocampal apoptosis in vivo. Postnatal hippocampal apoptosis was similar in CB1−/− mice and their wild-type littermates (9.9 ± 2.8 and 10.5 ± 2.0% of TUNEL-positive cells, respectively) and so was the case of adult brain hippocampus (Fig. 5B). These results confirm the absence of cannabinoid-induced apoptosis in nontransformed neural cells (Galve-Roperh et al., 2000; Guzmán, 2003) and provide additional support to cannabinoid regulation of the NP differentiation process toward the astroglial lineage.

GFAP mRNA levels (right) were determined after cannabinoid stimulation for 4 d. GFAP protein expression (bottom) with the indicated stimuli was determined after 24 h (gray bars) or 4 d (black bars). Nestin reporter activity (left) was determined in transfected NPs after 24 h (gray bars) or 4 d (black bars) as above. Nestin mRNA levels (right) and protein levels (bottom) after cannabinoid stimulation for 24 h (gray bars) or 4 d (black bars). Densitometric quantification is referred to the corresponding α-tubulin signal. Results correspond to three independent experiments. Representative Western blots are shown. Significantly different from controls, *p < 0.05; **p < 0.01.
The endocannabinoid system is involved in the control of postnatal astrogliogenesis in vivo
To investigate the relevance of the eCB system in the regulation of postnatal NP cell differentiation, we first analyzed CB₁ receptor expression by postnatal day 2 NPs in vivo. CB₂ was present in nestin-positive cells (Fig. 6A). RC2⁺ and vimentin⁺ radial glial cells (Fig. 6B,C) as well as double-positive nestin-GFAP progenitors (Fig. 6D) also expressed the cannabinoid receptor. Orthogonal reconstructions of confocal images unequivocally evidenced CB₁ expression in neural progenitors labeled with antibodies for RC2, vimentin, and phosphorylated vimentin (supplemental Fig. 1, available at www.jneurosci.org as supplemental material). Specifically, 20.8 ± 4.0% of RC2⁺ cells, 15.8 ± 2.9% of vimentin⁺ cells, and 30.3 ± 7.0% of nestin⁺GFAP⁺ cells expressed the CB₁ receptor. These observations are in agreement with nestin expression by RC2⁺ radial progenitors, which subsequently loose RC2 expression and acquire GFAP immunoreactivity during development (Kaneko et al., 2000; Gregg and Weiss, 2003; Tramontin et al., 2003; Merkle et al., 2004).

Because the CB₁ receptor is expressed by cells with the potential to act as NPs, we next investigated the impact of CB₁ deletion in the developing hippocampus by using CB₁ knock-out mice (Marsicano et al., 2002). Immunofluorescence quantification of BrdU⁺ cells showed a reduction of NP proliferation in CB₁⁻/⁻ mice versus wild-type littermates (Fig. 6E). Moreover, we determined by confocal microscopy and quantification of double S100B⁺/BrdU⁺ or NeuN⁺/BrdU⁺ cells whether in vivo differentiation of NPs was affected. This analysis of newly generated cells revealed the existence of reduced astrogliogenesis and increased neurogenesis in CB₁-deficient mice. These results support that CB₁ expression by postnatal NPs actively participates in the regulation of astroglial differentiation in vivo.

Expression of the endocannabinoid system in adult hippocampal progenitors
Both the CB₁ receptor and FAAH are known to be expressed in the dentate gyrus of the adult brain, with high levels of CB₁ in GABAergic interneurons and FAAH displaying a complementary postsynaptic distribution (Tsou et al., 1999; Egertova et al., 2003). However, it is unknown whether undifferentiated neural cells express the components of the eCB signaling system. We analyzed by confocal microscopy the expression of the CB₁ receptor and FAAH in mouse hippocampal sections together with specific neural cell markers. CB₁ expression was observed in nestin⁺ cells (Fig. 7A, top row), as well as in GFAP⁺ cells (Fig. 7A, bottom row) and PSA-NCAM⁺ cells (data not shown) of the subgranular zone. Conversely, FAAH immunoreactivity was present in nestin⁻ and GFAP⁺ cells (Fig. 7A), although we could hardly detect its colocalization with PSA-NCAM. Expression of CB₁ and FAAH was also evident in double nestin-GFAP-positive cells (type I nestin cells) (Fig. 7B), which comprise the adult hippocampal neural stem cell population (Seri et al., 2001; Fukuda et al., 2003; Kempermann et al., 2004). Orthogonal reconstruction of confocal sections confirmed the expression of CB₁ and FAAH in GFAP⁺ immunoreactive cells of the nestin-GFP hippocampal NPs (supplemental Fig. 2, available at www.jneurosci.org as supplemental material). Importantly, within the nestin⁺ cells, the type I subpopulation was selectively enriched in the expression of eCB system elements (CB₁ expression, 73 ± 10% of nestin⁺GFAP⁺ vs 27 ± 8% of nestin⁺GFAP⁻ cells; FAAH expression, 82 ± 5% of nestin⁺GFAP⁺ cells vs 18 ± 10% of nestin⁺GFAP⁻ cells). Considering that nestin⁺ progenitor cells with astrogial features represent the best-defined NP cell population resident in the adult...
dentate gyrus (Alvarez-Buylla and Lim, 2004; Kempermann et al., 2004), these results show that CB₁ and FAAH are expressed by hippocampal progenitor cells in vivo, which would allow locally generated eCBs to target NP cells.

The endocannabinoid system is involved in the control of adult hippocampal astrogliogenesis in vivo

The functional relevance of the eCB system in adult neurogenesis was determined in the subgranular zone of the dentate gyrus using CB₁ (Marsicano et al., 2002) and FAAH knock-out mice, which possess increased brain levels of eCBs (Cravatt et al., 2001). Adult mice were injected with BrdU and perfused 1 or 25 d later. Immunofluorescence studies showed that BrdU-positive cells were decreased in CB₁-deficient mice, which was significantly different in mice killed shortly after BrdU injection (Fig. 8A). In agreement, FAAH knock-out mice showed a complementary phenotype with enhanced hippocampal proliferation when compared with wild-type littermates (Fig. 8A). Similar to the proliferation analysis, CB₁ and FAAH knock-out mice showed opposite cell differentiation patterns (Fig. 8B). Thus, astroglial differentiation was lower in CB₁-deficient mice and enhanced in FAAH-deficient mice. Newly born neuron number remained unaffected (Fig. 8B), despite the observed changes in the percentage of BrdU⁺/NeuN⁺ cells in both knock-outs (Fig. 8C). These results confirm that the eCB signaling system plays an active role in the regulation of hippocampal NP proliferation and differentiation in vivo.

Discussion

Here we provide the first evidence that a functional eCB system present in NPs acts as an instructive progliogenic signal. These findings extend previous observations that suggested that CB₁ pharmacological stimulation modulates neurogenesis (Rueda et al., 2002) and NP proliferation (Jin et al., 2004; Aguado et al., 2005). In addition, impaired NP proliferation and neurosphere generation is observed in CB₁-deficient mice (Aguado et al., 2005). The role of the eCB system in the regulation of NP differentiation toward the astroglial lineage occurs in parallel with CB₁ receptor expression in vivo by postnatal RC2⁺ cells and adult hippocampal nestin type I cells. CB₁ deficiency results in impaired astrogliogenesis, whereas high eCB levels in vivo (FAAH⁻/⁻ mice) are associated with an opposite pattern of NP differentiation. Previous data also evidenced a role for the

Figure 6. Role of the endocannabinoid system in postnatal astrogliogenesis and neurogenesis in vivo. A, Low-magnification images of CB₁ expression in postnatal hippocampus sections stained for nestin, RC2, and vimentin, or nestin and GFAP. Scale bar, 40 μm. B–D, CB₁ expression (red) in progenitor cells as identified in green color by RC2 (B) and vimentin (C) immunoreactivity. Double-labeled nestin⁺/NeuN⁺ cells (green) GFAP⁺ (red) cells (D) also express the CB₁ receptor (blue). Cells were counterstained with Hoechst (blue). Scale bar, 10 μm. Inset shows coexpression of CB₁ and phosphorylated vimentin. Scale bar, 6 μm. E, Number of BrdU⁺ cells per section (left), number of BrdU⁺/NeuN⁺ cells that colocalize with S100β or NeuN (middle), and percentage of BrdU⁺ cells that coexpress S100β or NeuN (right) in the hippocampus of CB₁ knock-out mice (hatched bars) and their wild-type littermates (white bars). Significantly different from controls, *p < 0.05; **p < 0.01.
CB₁ receptor in adult NP proliferation, together with the potential involvement of the putative ionotropic eCB receptor, transient receptor potential vanilloid receptor 1 (TRPV1) (Jin et al., 2004). Although our study does not preclude the potential role of TRPV1 receptors in the regulation of NP cell differentiation, the critical role of the metabotropic cannabinoid receptor CB₁ is put forward by the existence of impaired astroglial differentiation in CB₁⁻/⁻ mice and the proliergic action exerted by WIN-55,212-2, a cannabinoid agonist that does not bind to TRPV1 (Piomelli, 2003). Likewise, a CB₁-mediated proliferative NP response has been reported recently by chronic in vivo administration of the synthetic cannabinoid agonist HU-210 (Δ⁹-tetrahydrocannabinol dimethyl heptyl) (Jiang et al., 2005). This response was accompanied by increased neurogenesis (astrogliogenesis was not determined) and was proposed to underlie cannabinoid antidepressant actions. Thus, in the restrictive environment toward neurogenesis that features most of the adult brain areas, the proliferative effect of the eCB system in NP cells may result in astrogliogenesis and/or neurogenesis depending on the intensity of cannabinoid stimulation (e.g., endogenous modulation vs pharmacological targeting) or the physiological context of NP regulation (e.g., normal vs injured brain). Considering the neuroprotective role of the eCB system (Mechoulam et al., 2002), its potential role in the regulation of endogenous NPs after brain injury and its precise involvement in the regulation of brain development remain as critical issues to be elucidated. Altogether, these observations open a new field in the investigation of cannabinoid regulation of NPs that, in the future, may provide a useful approach for the pharmacological modulation of adult neurogenesis.

The expression of the eCB system in NPs, together with their action on astroglial differentiation in vitro, suggests a direct mechanism of action that could rely on eCB-initiated signal transduction pathways. During cortical neurogenesis, sustained mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) signaling is required for neuronal generation and inhibition of gliogenesis (Ross et al., 2003). In this context, although in many cell types CB₁ activation leads to ERK stimulation (Guzmán, 2003), cannabinoids inhibit sustained ERK activation in NPs via attenuation of Rap-1/B-Raf signaling (Rueda et al., 2002). Alternatively, the eCB system may be targeted by the action of growth factors that are essential for the expansion and regulation of NPs from different brain areas in a variety of developmental stages (Temple, 2001). In particular, bFGF has been shown to regulate neural cell growth by increasing 2AG generation (Williams et al., 2003). Other potential candidates that may participate in cannabinoid regulation of NPs may involve, e.g., the bone morphogenetic protein family, Notch/Noggin, and leukemia inhibitory factor and other cytokines, which

---

**Figure 7.** Expression of the CB₁ receptor and FAAH in adult hippocampal NPs in vivo. A, Expression of CB₁ and FAAH (red) assessed by confocal microscopy as revealed by nestin or GFAP immunoreactivity (green) in mouse hippocampal sections. Cells were counterstained with TOTO-3 iodide (blue). Scale bar, 8 μm. B, Triple labeling showing the expression of CB₁ and FAAH (blue) in GFAP-immunoreactive (red) nestin-GFP⁻ cells. Representative images are shown.
are known to be involved in the control of neurogenesis or gliogenesis (Ross et al., 2003; Ever and Gaiano, 2005). To the best of our knowledge, there are not previous evidences pointing to any interaction between these signaling systems and eCBs, and so future research in our laboratory will be devoted to identify the precise cell signaling mechanism involved in eCB action, either directly as progliogenic signals per se (present report) or by influencing the aforementioned endogenious signaling systems.

Overall, the findings presented here add to the previously described roles of eCBs in the CNS, including the modulation of synaptic plasticity and neuronal excitability (Piomelli, 2003), as well as of cell survival (Meochulam et al., 2002). Astroglial cells are active players of the eCB system physiology. Astrocytes express CB₁ receptors (Rodriguez et al., 2001; Guzmán, 2003) and produce eCBs in a regulated manner (Walter et al., 2002), and cannabindoid stimulation protects them from apoptosis (Gómez del Pulgar et al., 2002). Although eCBs act during a limited and short period of time in the modulation of neurotransmitter release and neuronal excitability (Piomelli, 2003), their regulatory effects on NP differentiation are likely to influence neuronal circuitry in a long-term manner. Thus, the ability of the eCB system to modulate NP cell proliferation and differentiation may be of importance during brain development or contribute later to hippocampal adult brain plasticity. In summary, our observations add a novel role for the eCB system regulation of NP cell fate and extend previous evidences suggesting a potential role of the eCB system in brain development and its potential involvement in the pathogenesis of different neurodegenerative disorders.

References


Figure 8. Role of the endocannabinoid system in adult astrogliogenesis and neurogenesis in vivo. A, Number of BrdU⁺ cells per mouse in the hippocampus of CB₁ knock-out mice (hatched bars), FAAH knock-out mice (black bars), and their respective wild-type littermates (white bars) injected with BrdU and perfused 1 or 25 d later. B, Number of BrdU⁺ cells that colocalize with S100β or NeuN 25 d after the BrdU pulse. C, Percentage of BrdU⁺ cells that coexpress S100β or NeuN. Significantly different from controls, *p < 0.05; **p < 0.01.


